Complement 5b-9 complex-induced alterations in human RPE cell physiology

Medical Science Monitor

Volumn 16, Issue 1, 2010, Pages

  Li, Wenbo ^a   Chen, Song ^a   Ma, Minwang ^a   Qian, Jiangyuan ^a   Ma, Xiubin ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenic factor; C5b 9; Calcium ion; Choroidal neovascularization; Retinal pigment epithelium

Indexed keywords

ANGIOGENIC FACTOR; CALCIUM ION; COMPLEMENT COMPONENT C5B; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; ELECTRON MICROSCOPY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; MICROSCOPY; MOLECULAR BIOLOGY; PIGMENT EPITHELIUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBRETINAL NEOVASCULARIZATION; UPREGULATION;

CALCIUM; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; CHOROIDAL NEOVASCULARIZATION; COMPLEMENT C5B; COMPLEMENT C9; DNA PRIMERS; HUMANS; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON; MULTIPROTEIN COMPLEXES; RETINAL PIGMENT EPITHELIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 75149184039     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Cohen SY, Creuzot-Garcher C, Darmon J et al: Types of choroidal revascularization in newly diagnosed exudative age-related macular degeneration. Br J Ophthalmol, 2007; 91: 1173-76
2. Chakravarthy U, Soubrane G, Bandello F et al: Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol, 2006; 90: 1188-96
3. Morris B, Imrie F, Armbrecht AM, Dhillon B: Age-related macular degeneration and recent developments: new hope for old eyes? Postgrad Med J, 2007; 83: 301-7
4. Bora PS, Sohn JH, Cruz JM et al: Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol, 2005; 174: 491-97
5. Sivaprasad S, Adewoyin T, Bailey TA et al: Estimation of systemic complement C3 activity in age-related macular degeneration. Arch Ophthalmol, 2007; 125: 515-19
6. Ramo K, Cashman SM, Kumar-Singh R: Evaluation of adenovirus-delivered Human CD59 as a potential therapy for AMD in a model of human membrane attack complex formation on murine RPE Invest Ophthalmol Vis Sci, 2008; 49: 4126-36
7. Narayanan R, Butani V, Boyer DS et al: Complement factor H polymorphism in age-related macular degeneration. Ophthalmology, 2007; 114: 1327-31
8. Leveziel N, Zerbib J, Richard F et al: Genotype-phenotype correlations for exudative age-related macular degeneration associated with homozygous HTRA1 and CFH genotypes. Invest Ophthalmol Vis Sci, 2008; 49: 3090-94
9. Seddon JM, Reynolds R, Maller J et al: Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci, 2009; 50: 2044-53
10. Bhakdi S, Tranum-Jensen J: Molecular nature of the complement lesion. Proc Natl Acad Sci, 1978; 75: 5655
11. Tranum-Jensen J, Bhakdi S, Bhadki-Lehnen B et al: Complement lysis: the ultrastructure and orientation of the C5b-9 complex on target sheep erythrocyte membranes. Scand J Immunol, 1978; 7: 45
12. Christiansen VJ, Sims PJ, Hamilton KK: Complement C5b-9 increases plasminogen binding and activation on human endothelial cells. Arteriosclerosis, Thrombosis and Vascular Biology, 1997; 17: 164-71
13. Seth A, Cui J, To E et al: Complement-associated deposits in the human retina. Invest. Ophthalmol Vis Sci, 2008; 49: 743-50
14. Zarbin MA: Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol, 2004; 122: 598-614
15. Hageman GS, Luthert PJ, Victor Chong NH et al: An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruchs membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res, 2001; 20: 705-32
16. Marx J: A clearer view of macular degeneration. Science, 2006; 311: 1704-5
17. akdi S, Tranum-Jensen J, Klump O:The terminal membrane C5b-9 complex of human complement. J Immunol,1980; 124: 2541-47
18. Shin ML, Hänsch G, Hu VW, Nicholson-Weller A: Membrane factors responsible for homologous species restriction of complement-mediated lysis: Evidence for a factor other than daf operating at the stage of C8 and C9. J Immunol, 1986; 136: 1777-82
19. Zalman LS, Brothers MA, Strauss KL: Inhibition of cytolytic lymphocytes by homologous restriction factor. Lack of species restriction. J Immunol, 1991; 146: 4278-81
20. Dormans TP, Swinkels DW, de Graaf J et al: Single-spin density-gradient ultracentrifugation vs gradient gel electrophoresis: two methods for detecting low-density-lipoprotein heterogeneity compared. Clin Chem, 1991; 37: 853-58
21. Maminishkis A, Chen S, Jalickee S et al: Confluent monolayers of cultured human fetal retinal pigment epithelium exhibit morphology and physiology of native tissue. Invest Ophthalmol Vis Sci, 2006; 47: 3612-24
22. Chaine G, Hullo A, Sahel J et al: Case-control study of the risk factors for age related macular degeneration. Br J Ophthalmol, 1998; 82: 996-1002
23. Yates JR, Moore AT: Genetic susceptibility to age-related macular degeneration. J Med Genet, 2000; 37: 83-87
24. Husain D, Ambati B, Adamis AP, Miller JW: Mechanisms of age-related macular degeneration. Ophthalmol. Clin North Am, 2002; 15: 87-91
25. Bora NS, Kaliappan S, Jha P et al: Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H. J Immunol, 2006; 177: 1872-78
26. Frank MM, Fries LF: The role of complement in inflammation and phagocytosis. Immunol Today, 1991; 12: 322-26
27. Kim YU, Kinoshita T, Molina H et al: Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med, 1995; 181: 151-59.
28. Soane L, Rus H, Niculescu F, Shin ML: Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of Bcl-2 and mediated by inhibition of Caspase-3 activation. J Immunol, 1999; 163: 6132-38
29. Carney DF, Lang TJ, Shin ML: Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. J Immunol, 1990; 145: 623-29
30. Ozawa K, Szallasi Z, Kazanietz MG et al: Ca(2+)-dependent and Ca(2+)-independent isozymes of protein kinase C mediate exocytosis in antigen-stimulated rat basophilic RBL-2H3 cells. Reconstitution of secretory responses with Ca2+ and purified isozymes in washed permeabilized cells. J Biol Chem, 1993; 268: 1749-56
31. Garza A, Vega R, Soto E: Cellular mechanisms of lead neurotoxicity. Med Sci Monit, 2006; 12(3): RA57-65
32. Carla M, Ribeiro P, Paradiso AM et al: Chronic airway infection/inflammation induces a Ca2+i-dependent hyperinflammatory response in human cystic fibrosis airway epithelia. J Biol Chem, 2005; 280: 17798-806
33. Casares FM, Mantione K: Pesticides may be altering constitutive nitric oxide release, thereby compromising health. Med Sci Monit, 2006; 12(10): RA235-40
34. McLaughlin AP, De Vries GW: Role of PLCgamma and Ca(2+) in VEGF- and FGF-induced choroidal endothelial cell proliferation. Am J Physiol Cell Physiol, 2001; 281: 1448-56
35. th-century mechanisms, 21st- century therapies. Invest Ophthalmol Vis Sci, 1997; 38: 1647-52
36. Bates DO, Curry FE: Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway. Am J Physiol, 1997; 273: 687-94
37. Wood A, Wing MG, Benham CD, Compston DA: Specific induction of intra-cellular calcium oscillation by complement membrane attack on oligodendroglia. J Neurosci, 1993; 13: 3319-21
38. Daniels RH, Williams BD, Morgan BP: Human rheumatoid synovial cell stimulation by the complement membrane attack complex and other poreforming toxins in vitro: the role of calcium in cell activation. Immunology, 1990; 71: 312-16
39. Niculescu F, Rus H: Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells. Immunol Res, 2001; 24: 191-99
40. Burger A, Wagner C, Hug F, Hänsch GM: Up-regulation of intracellular calcium, cyclic adenosine monophospate and fibronectin synthesis in tubuar epithelial cells by complement. Eur J Immunol, 1999; 29: 1188-93
41. Jośko J, Gwozdz B, Jȩdrzejowska-Szypułka H, Hendryk S: Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit 2000; 6(5): 1047-1052
42. Zhang Y, Li M, Yao Q, Chen C: Recent advances in tumor hypoxia: Tumor progression, molecular mechanisms, and therapeutic implications. Med Sci Monit, 2007; 13(10): RA175-80
43. Marek A, Brodzicki J, Liberek A, Korzon M: TGF-beta (transforming growth factor-beta) in chronic inflammatory conditions - a new diagnostic and prognostic marker? Med Sci Monit, 2002; 8: RA145-51
44. Bashshur ZF, Haddad ZA, Schakal AR et al: Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol, 2009; 148: 59-65
45. Rein DB, Wittenborn JS, Zhang X et al: Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol, 2009; 127: 533-40
46. Yip PP, Woo CF, Tang HH, Ho CK: Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol. 2009; 93: 754-58
47. Kaiser PK, Boyer DS, Garcia R et al: Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology, 2009; 116: 747-55